Weekly Recap | ELIL.US +2.58%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.ELIL.US rose 2.58% this week to $33.041, while the S&P 500 fell 0.47%, leaving the ETF about 3.05 percentage points ahead of the benchmark. The week started weak, with a dip to $31.34 on Monday, then recovered as volume picked up on Tuesday and hit a high of $35.48 on Thursday before pulling back to the $33 area on Friday. The weekly range was 12.96%.
The Week
ELIL.US rose 2.58% this week to $33.041, while the S&P 500 fell 0.47%, leaving the ETF about 3.05 percentage points ahead of the benchmark. The week started weak, with a dip to $31.34 on Monday, then recovered as volume picked up on Tuesday and hit a high of $35.48 on Thursday before pulling back to the $33 area on Friday. The weekly range was 12.96%.
Eli Lilly This Week
Eli Lilly gained 1.31% to $1,273.46. The stock opened lower on Monday, turned higher on Tuesday alongside weight-loss and AI drug-delivery news, traded above $1,300 intraday, and then softened on Friday after touching a weekly high of $1,321.21 on Thursday. Its weekly range of 6.6% was much narrower than the 12.96% swing in this 2x ETF.
Leverage & Decay
This product tracks twice the daily move in Eli Lilly, not twice the weekly move. With the underlying up 1.31% on the week, the theoretical 2x cumulative return was about +2.62%; the actual result was +2.58%, a gap of −0.04%. That gap comes from daily rebalancing. The underlying fell, then rose, then pulled back, so the compounding path drifted slightly from a straight-line 2x calculation. In a trending market the drag is small; in a choppy one the gap tends to widen.
Eli Lilly News
Lilly’s headlines this week centred on three areas: Omvoh hit its primary endpoint in a Phase 3 trial for paediatric ulcerative colitis; the company signed a $1.1bn AI drug-delivery deal with METiS TechBio; and it broke ground on a $5bn ADC plant in Virginia on Thursday. Novo Nordisk’s CagriSema weight-loss data also stirred discussion across the obesity-drug space. The underlying stock strengthened on Tuesday and Thursday, then gave back ground on Friday.
Eli Lilly — Analyst Ratings
Eli Lilly is covered by 33 institutions: 20 rate it buy, 6 overweight, 3 hold, 1 underweight, 1 sell, and 2 have no explicit view. The consensus rating is buy, with a consensus target of $1,331.55, about 4.56% above the latest close of $1,273.46. Targets range from $930 to $1,600, a wide spread. The stock ranks first within the pharmaceutical industry on this measure.
The Week Ahead
Eli Lilly reports third-quarter fiscal 2026 results on Thursday, 29 October, with consensus estimates of $8.08 in EPS and $22.6bn in revenue. Before that, US durable goods orders and consumer confidence data land on 26–27 October. For this 2x product, the key variable next week remains the direction of Eli Lilly itself.
In Short
ELIL.US followed Eli Lilly higher and beat the S&P 500 by roughly 3 percentage points, while the leverage gap was essentially flat, suggesting the underlying moved in a mostly directional manner despite daily swings. The analyst picture leans favourable, with the consensus target above spot, but the wide target range points to real disagreement on valuation. On the latest trading day, medium and small-lot flows looked positive while large-lot flows were absent on both sides, so the signal is limited. Next up comes Lilly’s earnings report.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.